Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer
- 23 November 2015
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 27 (2) , 249-256
Abstract
Although tumor-infiltrating lymphocytes (TILs) have been associated with a favorable prognosis in triple-negative breast cancer (TNBC) patients, this marker is not currently considered robust enough for entering the clinical practice. In the present study, we assessed the clinical validity of the guidelines recently issued by the International TIL Working Group in a large retrospective series of well-annotated TNBC patients. TILs were evaluated in all the full-face H&E sections from 897 consecutive TNBC (i.e. tumors with P < 0.0001). Multivariable analysis confirmed that each 10% increase in TILs strongly predicted better survival, independent of patients' age, lymph node status, tumor size, histological grade, peritumoral vascular invasion and Ki-67 labeling index. Patients with LPBC had a 10-year survival rate of 71%, 84% and 96% for DFS, DDFS and OS, respectively. Stratified analysis revealed a positive correlation between TILs and OS across all the subgroups analyzed. Our data support the analytical validity of the recently issued TILs evaluation guidelines in the clinical practice.Keywords
This publication has 23 references indexed in Scilit:
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Annals of Oncology, 2015
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199Journal of Clinical Oncology, 2014
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Annals of Oncology, 2014
- New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escapeCurrent Opinion in Immunology, 2014
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialAnnals of Oncology, 2014
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98Journal of Clinical Oncology, 2013
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast CancerJournal of Clinical Oncology, 2010
- Immune infiltration in human tumors: a prognostic factor that should not be ignoredOncogene, 2009
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006